• Downloads
  • Contact Us
  • Directions
  • Deutsch Deutsch German de
  • English English English en
  • 简体中文 简体中文 Chinese (Simplified) zh-hans
Epitype GmbH
  • Products
  • About us
    • Management
    • Team
    • Research projects
    • Publications
    • Press
    • Jobs
  • Contact
    • Directions
    • Contact Us
  • News / Blog
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Press releases

Worldwide unique test for cervical cancer as a gamechanger for the healthcare system

Press Releases

Cancer is and remains one of the greatest health, medical and socio-political challenges of our time. This is also made clear by the World Health Organization’s (WHO) forecast, which predicts […]

Read more
17. September 2025/by Jan Mueller
https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png 0 0 Jan Mueller https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png Jan Mueller2025-09-17 09:52:242025-11-18 13:24:29Worldwide unique test for cervical cancer as a gamechanger for the healthcare system

Jena Biotechnology Company Files for Insolvency

Press Releases
Biotechnologieunternehmen aus Jena stellt Insolvenzantrag: oncgnostics GmbH

Jena, Thuringia, March 31, 2025. Jena-based Oncgnostics GmbH has filed for insolvency. The Gera District Court has ordered and appointed lawyer Kai Dellit from the law firm hww hermann wienberg […]

Read more
31. March 2025/by Admin Spinger
https://www.epitype.de/wp-content/uploads/2025/04/PM-Titelbild-oncgnostics-GmbH.png 321 845 Admin Spinger https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png Admin Spinger2025-03-31 11:15:552025-04-03 11:55:56Jena Biotechnology Company Files for Insolvency

Methylation Tests in Cervical Cancer Screening Could Reduce Invasive Procedures up to 75%

Press Releases
Ärztin schaut durch ein Kolposkop. Symbolbild für die Pressemeldung der oncgnostics GmbH: Methylierungstests beim Gebärmutterhalskrebs-Screening könnten invasive Verfahren um bis zu 75 % reduzieren.Peakstock / Shutterstock

Porto / Jena, November 26, 2024 – Methylation tests could significantly increase the accuracy of cervical cancer screening and reduce referrals for colposcopy, which would, in turn, put less strain […]

Read more
26. November 2024/by Admin Spinger
https://www.epitype.de/wp-content/uploads/2024/11/PM-Titel-Studie-1.png 321 845 Admin Spinger https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png Admin Spinger2024-11-26 12:49:152024-11-26 12:55:53Methylation Tests in Cervical Cancer Screening Could Reduce Invasive Procedures up to 75%

Methylation Testing for Tumor Detection: A Non-Invasive Alternative to Standard Diagnostics

Press Releases
MEDICA Düsseldorf 2024

Jena / Düsseldorf, November 7, 2024 – Molecular biological diagnostics offer a non-invasive alternative for cancer detection. oncgnostics GmbH will demonstrate this in Düsseldorf at MEDICA, one of the world’s […]

Read more
7. November 2024/by Admin Spinger
https://www.epitype.de/wp-content/uploads/2024/11/Blog-Titel-MEDICA.jpg 430 1132 Admin Spinger https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png Admin Spinger2024-11-07 09:38:502024-11-13 09:42:47Methylation Testing for Tumor Detection: A Non-Invasive Alternative to Standard Diagnostics

Oncgnostics expands international distribution

Press Releases
Oncgnostics expandiert im internationalen Vertrieb mit Seegeneoncgnostics GmbH

Jena, July 22 – Oncgnostics GmbH signs an agreement with Seegene Germany GmbH for the international distribution of its own tests. Dr. Alfred Hansel, Managing Director of Oncgnostics: “The agreement […]

Read more
22. July 2024/by Admin Spinger
https://www.epitype.de/wp-content/uploads/2024/07/Titelbild-PM-Seegene.jpg 321 600 Admin Spinger https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png Admin Spinger2024-07-22 10:22:532024-07-18 08:24:54Oncgnostics expands international distribution

Psychological stress in cervical cancer tabood

Press Releases
Symbolbild einer Suchmaschine: Medienstudie der oncgnostics GmbH. Psychische Belastung bei der Gebärmutterhalskrebs Vorsorge wird kaum redaktionell aufgebarbeitet.Shaily / shutterstock

Media study: A recent media study by Oncgnostics GmbH shows that, although the general media report on the topic of cervical cancer, they do not address the associated psychological stress […]

Read more
7. June 2024/by Admin Spinger
https://www.epitype.de/wp-content/uploads/2024/05/PM-Medienstudie-oncgnostics-GmbH.png 321 845 Admin Spinger https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png Admin Spinger2024-06-07 11:15:092024-06-07 11:15:09Psychological stress in cervical cancer tabood

Molecular biological cancer diagnostics close gaps in cancer screening

Press Releases
Molekularbiologische Krebs-Diagnostik - oncgnostics auf der MEDICA

Two tests for cervical cancer with different objectives in cervical cancer screening Liquid biopsy for rapid and gentle diagnosis of head and neck tumours Current studies: GynTect DNA methylation test […]

Read more
2. November 2023/by Admin Spinger
https://www.epitype.de/wp-content/uploads/2023/11/medica_duration_2023_03_cmyk.jpg 356 845 Admin Spinger https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png Admin Spinger2023-11-02 10:57:222023-11-02 10:57:22Molecular biological cancer diagnostics close gaps in cancer screening

Hong Kong firm invests in Jena-based Oncgnostics GmbH

Press Releases
2023 PM Oncgnostics Investment

Jena, September 05, 2023. The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a seven-digit Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics has developed the cancer […]

Read more
5. September 2023/by Admin Spinger
https://www.epitype.de/wp-content/uploads/2023/09/2023-PM-Oncgnostics-Investment.png 321 845 Admin Spinger https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png Admin Spinger2023-09-05 13:55:492023-09-15 09:10:17Hong Kong firm invests in Jena-based Oncgnostics GmbH

Cancer diagnostics of the future thanks to highly informative biomarkers

Press Releases
The team of oncgnostics

oncgnostics at Medica 2022: Cervical cancer screening test conquers China Establishing early detection of head and neck tumours First study results for screening test for vulva and vaginal cancer At […]

Read more
8. November 2022/by TowerPR
https://www.epitype.de/wp-content/uploads/2022/11/221011-ONC-Team_22_Webseite-scaled.jpg 974 2560 TowerPR https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png TowerPR2022-11-08 11:50:512022-11-08 11:59:31Cancer diagnostics of the future thanks to highly informative biomarkers

German oncgnostics GmbH‘s innovation in the area of cervical cancer diagnostics now also available in China

Press Releases
Proudktfoto - zwei Karton von GynTect gestapelt Foto: GenoDxGeneoDx

GynTect receives approval in China Jena, August 25, 2022 – The cervical cancer screening test GynTect is now available to physicians and patients in China, the world’s most populous country. […]

Read more
25. August 2022/by Admin Spinger
https://www.epitype.de/wp-content/uploads/2022/08/2022-08-23-Blog-Titel-China-zulassung.jpg 321 845 Admin Spinger https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png Admin Spinger2022-08-25 14:21:142023-07-04 10:20:31German oncgnostics GmbH‘s innovation in the area of cervical cancer diagnostics now also available in China
Page 1 of 41234
  • Management
  • Team
  • Research projects
  • Publications
  • Press
  • Jobs

Recent Posts

  • Worldwide unique test for cervical cancer as a gamechanger for the healthcare system
  • Jena Biotechnology Company Files for Insolvency
  • Bachelor thesis in biotechnology companies: From research to diagnostics 
  • Methylation Tests in Cervical Cancer Screening Could Reduce Invasive Procedures up to 75%
  • Methylation Testing for Tumor Detection: A Non-Invasive Alternative to Standard Diagnostics

Epitype GmbH

The Epitype GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.

Epitype GmbH is working according to ISO 13485 standards in research, development, production and management.

Recent Posts

  • Worldwide unique test for cervical cancer as a gamechanger for the healthcare system
  • Jena Biotechnology Company Files for Insolvency
  • Bachelor thesis in biotechnology companies: From research to diagnostics 

Contact

Epitype GmbH
Löbstedter Str. 41
07749 Jena
Germany

Phone: +49 (0)3641 5548500

Email: contact[at]epitype.de
Internet: www.epitype.de

© 2015 - 2025 Epitype GmbH Jena Germany
  • Start
  • Imprint
  • Contact Us
  • Privacy policy
Scroll to top

Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Learn moreI accept

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy policy
Einstellungen akzeptierenVerberge nur die Benachrichtigung
Epitype GmbH
Einwilligung verwalten

Um Ihnen ein optimales Erlebnis zu bieten, verwenden wir Technologien wie Cookies, um Geräteinformationen zu speichern und/oder darauf zuzugreifen. Wenn Sie diesen Technologien zustimmen, können wir Daten wie das Surfverhalten oder eindeutige IDs auf dieser Website verarbeiten. Wenn Sie Ihre Einwilligung nicht erteilen oder zurückziehen, können bestimmte Merkmale und Funktionen beeinträchtigt werden.

Funktional Always active
Die technische Speicherung oder der Zugang ist unbedingt erforderlich für den rechtmäßigen Zweck, die Nutzung eines bestimmten Dienstes zu ermöglichen, der vom Teilnehmer oder Nutzer ausdrücklich gewünscht wird, oder für den alleinigen Zweck, die Übertragung einer Nachricht über ein elektronisches Kommunikationsnetz durchzuführen.
Präferenzen
Die technische Speicherung oder der Zugriff ist für den rechtmäßigen Zweck der Speicherung von Präferenzen erforderlich, die nicht vom Abonnenten oder Benutzer angefordert wurden.
Statistiken
Die technische Speicherung oder der Zugriff, der ausschließlich zu statistischen Zwecken erfolgt. Die technische Speicherung oder der Zugriff, der ausschließlich zu anonymen statistischen Zwecken verwendet wird. Ohne eine Vorladung, die freiwillige Zustimmung deines Internetdienstanbieters oder zusätzliche Aufzeichnungen von Dritten können die zu diesem Zweck gespeicherten oder abgerufenen Informationen allein in der Regel nicht dazu verwendet werden, dich zu identifizieren.
Marketing
Die technische Speicherung oder der Zugriff ist erforderlich, um Nutzerprofile zu erstellen, um Werbung zu versenden oder um den Nutzer auf einer Website oder über mehrere Websites hinweg zu ähnlichen Marketingzwecken zu verfolgen.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
Einstellungen ansehen
  • {title}
  • {title}
  • {title}